Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
The World Health Organisation (WHO), has felt the need to conduct this training to build local capacities in poor countries to bridge the gap and enhance local production
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The trial will be conducted across eight sites in Maharashtra
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
PPH is associated with almost 20 per cent of maternal mortality in India
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
Subscribe To Our Newsletter & Stay Updated
